Every Form 4 that Contineum Therapeutics, Inc. (CTNM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics, Inc. (CTNM) reported that CEO and President Carmine N. Stengone exercised options to acquire 2,500 shares of Class A common stock on September 8, 2026 at an exercise price of $1.01 per share and sold 2,500 shares on the same day at a weighted average price of $16.4566 per share. The option was granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, is fully vested, and after this exercise 274,430 option shares from this award remain outstanding. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics, Inc. CEO and President Carmine N. Stengone exercised stock options for 2,500 shares of Class A common stock at an exercise price of $1.01 per share and sold 2,500 shares at a weighted average price of $16.0116 per share, with trades between $16.00 and $16.06. The options were granted under the company’s 2012 Equity Incentive Plan and are fully vested, leaving 276,930 options outstanding after the exercise. All reported transactions on August 3, 2026 were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported paired option exercises and stock sales in Class A Common Stock. He exercised options covering 1,040 shares at $1.01 per share and sold 1,040 shares at $16.00 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock. He exercised stock options for 2,500 shares at $1.01 per share and sold 2,500 shares at $16.00 per share on July 8, 2026. These trades were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, he holds 17,217 shares directly and 279,430 stock options expiring on February 24, 2030.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported mixed equity transactions in Class A Common Stock. On June 30 and July 1, he sold a total of 37,179 shares in open-market trades at weighted average prices around $15.67–$16.24 per share under a pre-arranged Rule 10b5-1 trading plan. He also exercised stock options for 33,009 shares at an exercise price of $1.01 per share, converting options into common stock. After these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse, along with 34,297 fully vested stock options that remain exercisable.
Contineum Therapeutics, Inc. executive Tim Watkins, CMO & Head of Development, reported an exercise-and-sell transaction in Class A Common Stock. On June 30, 2026, he exercised stock options to acquire 10,833 shares at an exercise price of $4.50 per share and sold 10,833 shares in open-market trades at a weighted average price of $16.0242 per share, with individual sale prices ranging from $16.00 to $16.15. The sale was carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he directly holds 19,794 shares of Class A Common Stock, which includes 8,961 shares acquired through the company’s Employee Stock Purchase Plan, and retains 238,334 stock options with a $4.50 exercise price expiring on April 27, 2035, subject to continued vesting.
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and on the same day sold 10,000 shares in an open-market transaction. The sale used a weighted average price of $16.008 per share, with individual trades between $16.00 and $16.12.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, Stengone directly holds 17,217 Class A shares, including 5,605 acquired through the company’s Employee Stock Purchase Plan, and retains stock options covering 118,417 shares at $1.26 and 281,930 shares at $1.01 exercise prices.
Contineum Therapeutics director Diego Miralles received a new stock option grant as part of standard board compensation. He was awarded options over 19,000 shares of Class A common stock at an exercise price of $14.19 per share under the company’s 2024 Equity Incentive Plan.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic option for 19,000 shares after each regular annual meeting for continuing non-employee directors. The options vest in full on the earlier of June 26, 2027, or the next regular annual stockholder meeting, subject to his continuous service, and expire on June 25, 2036. Following this grant, Miralles holds 19,000 stock options directly.
Contineum Therapeutics, Inc. director Lori Lyons-Williams received a grant of stock options covering 19,000 shares of Class A Common Stock under the company’s 2024 Equity Incentive Plan. The options have an exercise price of $14.19 per share and expire on June 25, 2036.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic annual option award to each continuing non-employee director after the regular annual stockholder meeting. The option vests in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, subject to her continuous service.
Contineum Therapeutics director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the 2024 Equity Incentive Plan as part of the non-employee director compensation program. They vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, assuming continuous board service.
Contineum Therapeutics director Evert B. Schimmelpennink received a routine equity grant. He was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the 2024 Equity Incentive Plan. These options vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting and expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.
Contineum Therapeutics director Troy A. Ignelzi received a grant of stock options for 19,000 shares of Class A Common Stock. The options were awarded under the company’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program at an exercise price of $14.19 per share.
The option grant vests in full on the earlier of June 26, 2027 or the next regular annual meeting of stockholders, assuming continuous board service. Following this award, Ignelzi holds stock options for 19,000 underlying shares directly.
Contineum Therapeutics director Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. The options have a $14.19 exercise price, were granted under the 2024 Equity Incentive Plan, and vest in full on June 26, 2027 or at the next annual stockholder meeting.
Contineum Therapeutics, Inc. director Sarah Boyce received a grant of stock options covering 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the company’s 2024 Equity Incentive Plan as part of its Non-Employee Director Compensation Program.
According to the terms, the options will vest in full on the earlier of June 26, 2027, or the next regular annual meeting of stockholders, provided she continues to serve as a director. This is a routine compensation-related award and does not involve any open-market buying or selling of shares.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock at a weighted average price of $13.1564 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
After this transaction, he holds 139,372 shares directly and 10,110 shares indirectly through his spouse. His holdings include 3,268 shares purchased through Contineum’s Employee Stock Purchase Plan on May 15, 2026.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported open-market sales of company stock. On May 1, 2026, he sold a total of 4,170 shares of Class A Common Stock in two transactions at weighted average prices of $13.06 and $13.84 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
After these sales, he holds 143,542 shares directly and 6,842 shares indirectly through his spouse. The prices reflect multiple trades within reported ranges between $12.69 and $13.86 per share.
Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock. The shares were sold at a weighted average price of $13.4326 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
After the sale, he directly holds 147,712 shares. In addition, 6,842 shares are held indirectly by his spouse. The sale price reflected multiple trades within a range of $13.08 to $13.60 per share.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of Class A common stock. He sold 4,170 shares on March 2, 2026 at a weighted average price of $15.0084 per share, in multiple trades between $14.60 and $15.41.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After this transaction, Lorrain directly holds 151,882 shares of Class A common stock, and an additional 6,842 shares are held indirectly by his spouse.
Contineum Therapeutics CMO and Head of Development Tim Watkins reported option-related share movements. On March 2, 2026, he exercised stock options covering 3,611 shares of Class A common stock at $4.50 per share, increasing his option-related holdings to 249,167 shares. He then sold 3,611 shares of Class A common stock in the open market at a weighted average price of $15.0153 per share, with trades executed between $14.60 and $15.41, leaving no shares from this lot outstanding. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics CEO Carmine N. Stengone reported option exercises and share sales in Contineum Therapeutics, Inc. He exercised stock options for 7,100 shares of Class A common stock at an exercise price of $1.26 per share on February 24 and 25, 2026. On the same dates, he sold a total of 7,100 Class A common shares in open-market transactions at weighted average prices of $16.0195 and $16.0155 per share, with actual prices ranging from $16.00 to $16.15. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he held 14,954 shares of Class A common stock and 120,917 stock options directly.
Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain exercised stock options and sold shares in pre-planned trades. He exercised options covering 8,124 shares of Class A common stock at an exercise price of $1.01 per share, then sold 8,124 shares in open-market transactions at weighted average prices around $16 per share under a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock, with an additional 6,842 shares held indirectly by his spouse.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported a small set of stock transactions. On February 19, 2026, he exercised stock options for 100 shares of Class A common stock and acquired those 100 shares at a price of $1.01 per share.
On the same date, he sold 100 shares of Class A common stock at a price of $16.00 per share in an open-market transaction. After these transactions, he held 156,052 shares of Class A common stock directly and 6,842 shares indirectly through his spouse. The filing notes the transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and related share sale. On February 11, 2026, he exercised 400 stock options at an exercise price of $1.26 per share, receiving 400 shares of Class A common stock.
That same day, he sold 400 Class A common shares at $16.00 per share in an open-market transaction. After these trades, he directly owned 14,954 Class A shares and 128,017 stock options. The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025, and that the stock options are fully vested and exercisable.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. exercised stock options and sold a small block of shares. On February 11, 2026, he exercised options for 400 shares of Class A common stock at $1.01 per share and then sold 400 shares at $16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock and held 75,530 stock options, with an additional 6,842 shares held indirectly by his spouse.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. reported planned stock sales under a prearranged Rule 10b5-1 trading plan. On February 3, 2026, the insider sold 3,000 shares of Class A common stock at a weighted average price of $14.8229 and 1,170 shares at a weighted average price of $15.2451. The prices in each trade reflect multiple executions within disclosed ranges. After these transactions, the officer directly held 156,052 shares of Class A common stock and had an additional 6,842 shares reported as indirectly owned by a spouse.
Contineum Therapeutics reported that its General Counsel and Corporate Secretary, John Stephen Healy, received a grant of stock options on January 30, 2026. The award covers 206,411 shares of Class A common stock at an exercise price of $14.26 per share.
The options were granted under the company’s 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, conditioned on Healy’s continued service with the company. Following this grant, he beneficially owns 206,411 stock options, held directly.
Contineum Therapeutics reported a new equity award for its Chief Financial Officer, Peter Slover. On 01/30/2026, he received a grant of stock options to buy 192,000 shares of Class A common stock at an exercise price of $14.26 per share under the company’s 2024 Equity Incentive Plan. These options vest in equal monthly installments over 48 months, conditioned on his continuous service, and he beneficially owns 192,000 derivative securities directly after the grant.
Contineum Therapeutics, Inc. granted CEO and President Carmine N. Stengone a stock option award on January 30, 2026 under its 2024 Equity Incentive Plan. The grant covers 445,000 stock options with an exercise price of $14.26 per share.
The options relate to Class A common stock and vest in equal monthly installments over 48 months, as long as Mr. Stengone continues in service. The options expire on January 29, 2036, and all 445,000 derivative securities are reported as directly owned following the grant.
Contineum Therapeutics granted stock options to Chief Scientific Officer Lorrain Daniel S. on January 30, 2026 under its 2024 Equity Incentive Plan. The award covers options to buy 160,000 shares of Class A common stock at an exercise price of $14.26 per share, expiring on January 29, 2036. These options vest in equal monthly installments over 48 months, conditioned on the executive’s continued service.
An additional grant of stock options to purchase 6,500 shares of Class A common stock at $14.26 per share was made in connection with the continuous service of the executive’s spouse at the company. These options have the same 48‑month monthly vesting schedule and are reported as indirectly owned through the spouse.
Contineum Therapeutics executive Tim Watkins reported option exercises, share sales, and a new option grant. On 01/28/2026 he exercised 3,611 stock options at an exercise price of $4.50 per share, acquiring 3,611 shares of Class A common stock.
That same day, he sold 2,800 shares at a weighted average price of $14.0861 and 811 shares at a weighted average price of $14.4848, leaving no directly held common shares after the transactions. These sales were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.
In a separate transaction on 01/30/2026, Watkins received an award of 160,000 stock options with a $14.26 exercise price, expiring on 01/29/2036. These options vest in equal monthly installments over 48 months, subject to his continuous service.